[go: up one dir, main page]

DE602006006903D1 - Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems - Google Patents

Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems

Info

Publication number
DE602006006903D1
DE602006006903D1 DE602006006903T DE602006006903T DE602006006903D1 DE 602006006903 D1 DE602006006903 D1 DE 602006006903D1 DE 602006006903 T DE602006006903 T DE 602006006903T DE 602006006903 T DE602006006903 T DE 602006006903T DE 602006006903 D1 DE602006006903 D1 DE 602006006903D1
Authority
DE
Germany
Prior art keywords
nervous system
central nervous
neuroregeneration
ghrp
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006006903T
Other languages
English (en)
Inventor
Del Barco Herrera Diana Garcia
Nieto Gerardo Enrique Guillen
Acosta Jorge A Berlanga
Almeida Freya De Los Milagros Freyre
Vera Danay Cibrian
Arias Eduardo Penton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of DE602006006903D1 publication Critical patent/DE602006006903D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006006903T 2005-03-02 2006-02-24 Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems Active DE602006006903D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20050043A CU23529A1 (es) 2005-03-02 2005-03-02 Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
PCT/CU2006/000001 WO2006092106A2 (es) 2005-03-02 2006-02-24 Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune.

Publications (1)

Publication Number Publication Date
DE602006006903D1 true DE602006006903D1 (de) 2009-07-02

Family

ID=40280698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006006903T Active DE602006006903D1 (de) 2005-03-02 2006-02-24 Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems

Country Status (18)

Country Link
US (1) US20100093616A1 (de)
EP (1) EP1870106B1 (de)
JP (1) JP5001180B2 (de)
KR (1) KR101255200B1 (de)
CN (1) CN101180044B (de)
AT (1) ATE431743T1 (de)
AU (1) AU2006220154B2 (de)
BR (1) BRPI0607844B8 (de)
CA (1) CA2600628C (de)
CU (1) CU23529A1 (de)
DE (1) DE602006006903D1 (de)
ES (1) ES2327562T3 (de)
MX (1) MX2007010717A (de)
MY (1) MY142494A (de)
PT (1) PT1870106E (de)
RU (1) RU2403913C2 (de)
WO (1) WO2006092106A2 (de)
ZA (1) ZA200707020B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
CU24591B1 (es) * 2018-08-21 2022-04-07 Ct Ingenieria Genetica Biotecnologia Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento
ES2967696T3 (es) 2019-04-08 2024-05-03 Giuseppe Scalabrino Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9804064D0 (sv) * 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
CU23043A1 (es) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
EP1506997A1 (de) * 2003-08-14 2005-02-16 NeuroProgen GmbH Leipzig Verfahren zur Erzeugung von neuronalen Stammzellen

Also Published As

Publication number Publication date
CA2600628A1 (en) 2006-09-08
US20100093616A1 (en) 2010-04-15
MX2007010717A (es) 2007-10-12
EP1870106B1 (de) 2009-05-20
CA2600628C (en) 2013-04-09
BRPI0607844B1 (pt) 2018-08-28
BRPI0607844B8 (pt) 2021-05-25
PT1870106E (pt) 2009-08-25
ZA200707020B (en) 2009-08-26
ATE431743T1 (de) 2009-06-15
BRPI0607844A2 (pt) 2010-10-19
JP5001180B2 (ja) 2012-08-15
EP1870106A2 (de) 2007-12-26
RU2007136280A (ru) 2009-04-10
WO2006092106A3 (es) 2006-12-14
CU23529A1 (es) 2010-06-17
KR101255200B1 (ko) 2013-04-23
ES2327562T3 (es) 2009-10-30
AU2006220154A1 (en) 2006-09-08
JP2008531607A (ja) 2008-08-14
AU2006220154B2 (en) 2010-05-27
MY142494A (en) 2010-11-30
WO2006092106A2 (es) 2006-09-08
CN101180044A (zh) 2008-05-14
KR20070107790A (ko) 2007-11-07
RU2403913C2 (ru) 2010-11-20
CN101180044B (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
BR112013033417A2 (pt) compostos terapêuticos e métodos relacionados de uso
HN2012000012A (es) Inhibidores de bace
CR9493A (es) Heteroarilamidas (3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
PE20142367A1 (es) Formulaciones de imiquimod
BR112014007675A2 (pt) tratamento de doença articular degenerativa
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CL2021001209A1 (es) Constructos de suministro para transcitosis y métodos relacionados
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
UY28786A1 (es) Terapia en la que se utilizan derivados del 1-amino ciclohexano para el tratamiento de los trastornos de conducta asociados con la enfermedad de alzheimer
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
DOP2018000218A (es) Inhibidor de esterasa c1 conjugado y sus usos
ATE507827T1 (de) Behandlung pervasiver entwicklungsstörungen
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ZA200707020B (en) Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
EP4566668A3 (de) Neurotoxine zur minimierung von narbenbildung
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
MX2024001744A (es) Formulaciones de radiprodil.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition